Melflufen plus dexamethasone in relapsed/refractory multiple myeloma: long‐term survival follow‐up from the Phase II study O‐12‐M1

An updated survival analysis was conducted for the Phase II study O‐12‐M1 of melphalan flufenamide (melflufen) plus dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM) with two or more prior lines of therapy (including bortezomib and lenalidomide). Partial response or better w...

Descripción completa

Detalles Bibliográficos
Autores principales: Bringhen, Sara, Voorhees, Peter M., Plesner, Torben, Mellqvist, Ulf‐Henrik, Reeves, Brandi, Sonneveld, Pieter, Byrne, Catriona, Nordström, Eva, Harmenberg, Johan, Obermüller, Jakob, Richardson, Paul G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Haematological malignancy – Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8248157/
https://www.ncbi.nlm.nih.gov/pubmed/33403663
http://dx.doi.org/10.1111/bjh.17302

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8248157/
https://www.ncbi.nlm.nih.gov/pubmed/33403663
http://dx.doi.org/10.1111/bjh.17302

Ejemplares similares